therapeutic targets for cellular protection in AD. 21 Several mitochondrial proteins have been shown to interact directly with Aβ, possibly influencing mitochondrial metabolism. 22 The amyloid-binding alcohol dehydrogenase (ABAD) enzyme, also known as 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), is one such Aβ binding protein. 23 The Aβ-ABAD interaction promotes the enzyme to undergo functional changes, resulting in altered enzymatic activity, elevated levels of toxic metabolites, enhanced oxidative stress and mitochondrial and synaptic dysfunction. [24] [25] [26] Studies using an ABAD decoy peptide consisting of the ABAD amino acid residues responsible for interaction with Aβ, have been shown to disrupt the interaction between ABAD and Aβ, reducing Aβ-induced mitochondrial and neuronal toxicity and improving learning and memory in AD mice models. 25, 27 Further, the direct inhibition of the ABAD enzyme has been
shown to have neuroprotective effects in terms of reducing cell stress via decreased generation of reactive oxygen species, improved mitochondrial respiration, and stabilization of estradiol levels. 28, 29 Thus both the direct inhibition of ABAD enzyme and the disruption of the Aβ-ABAD interaction present possible approaches for AD treatment. 29 Due to the multifactorial nature of AD aetiology, the question whether a single-target-directed drug could yield therapeutic effect in AD treatment has led scientists to focus still more on the emerging multitarget-directed ligand (MTDL) approach. 30 Simultaneous modulation of several pathological events of the ongoing disease may then contribute to therapeutic effect of progressing AD. 31 The MTDL approach has been employed by many research groups [32] [33] [34] [35] and has shown success, for example in the case of the compound ladostigil 36 which has reached clinical trials. 37 Exploiting the advantage of conjunctive approach,
we designed a series of compounds combining known scaffolds of MAO and ABAD inhibitors to introduce MAO inhibitory activity into frentizole moiety and explore structural inhibitory features of both MAO and ABAD scaffolds. Xie et al. observed that the FDA approved drug, frentizole ( Fig. 1: A) , acted as a weak inhibitor of the Aβ-ABAD interaction (IC 50 = 200 μM) and described a novel class of frentizole-based benzothiazolyl (thio)ureas acting as inhibitors of the Aβ-ABAD interaction. 38 Relatively minimal modifications of the distal phenyl ring substitution also allowed phosphonate analogues of the same scaffold to act as direct ABAD inhibitors, yielding two compounds that inhibited ABAD with IC 50 values of 52.7 μM and 341.9 μM. 39, 40 Recently, low micromolar scale ABAD inhibitors were reported. 41 Furthermore, a fused bicyclic system comprised of 5-and 6-membered rings (i.e. indane) represents core scaffold of several MAO inhibitors (e.g. rasagiline or ladostigil). The carbocyclic system is not exclusive for MAO inhibition, since other bicyclic and heterocyclic scaffolds have been reported to inhibit MAO. 35, 42 In this case, the aminoindane moiety has been replaced with an isosteric indole ring ( Fig. 1: B) and further incorporated into frentizole scaffold ( Fig. 1: A) . The frentizole urea linker was changed to the analogous thiourea linker since the similar thiocarbonyl scaffold was previously identified to be beneficial for ABAD inhibition. 43 The distal phenyl ring presented in frentizole was modified by various substitution patterns that have been introduced to investigate structure and activity relationship of this scaffold ( Fig. 1: C) .
Fig. (1). Conjunctive design approach combining frentizole (A) and ladostigil (B) to novel MAO/ABAD inhibitors (C).
In this study we report the synthesis and in vitro evaluation of a novel series of these indolyl thiourea compounds. In vitro evaluation includes the inhibition of the MAO-A, MAO-B and ABAD enzymes in direct assays. The inhibition of horseradish peroxidase (HRP, used in the coupled assay for MAO activity) was also evaluated, but this inhibition was identified as a confounding factor in the initial evaluation of the novel compounds. Acute toxicity was determined via the MTT assay using the CHO-K1 cell line and the most promising compounds were selected for a PAMPA assay to evaluate their ability to cross the blood-brainbarrier (BBB).
Results

Chemistry
A two-step synthesis was performed to generate the desired disubstituted indolyl thioureas 3-23.
Electron-rich aromatic amines were readily converted to the corresponding isothiocyanates (Scheme 1, conditions a), 44 whereas electron poor aromatic amines required stronger basic conditions (Scheme 1, conditions b) to achieve conversion of the amine to a dithiocarbamic salt with following isothiocyanate (2) formation. 44, 45 The isothiocyanates (2) were coupled with 1H-indol-5-amine to generate the disubstituted thioureas 3-23 (Table 1) in moderate to excellent yields (38-99%). 46 The reverse process with conversion of 1H-indol-5-amine to isothiocyanate and subsequent coupling step (Scheme 1, conditions d) with the second amine was used for final compounds with free phenolic group, where complete conversion to dithiocarbamic salt does not proceed quantitatively within reasonable time period. However, the outlined process in Scheme 1 was favoured due to higher reactivity of amines in the coupling step (Scheme 1, conditions d), resulting in higher overall yields. The procedure also allowed compounds to be more readily purified by subsequent column chromatography rendering final compounds . The experimental section gives a detailed description of which procedure was used for each amine. An initial screen using a coupled fluorescence assay to assess MAO inhibition by the novel indole thiourea compounds suggested potent inhibition in the micromolar range that was not replicated in the direct spectrophotometric assay. The coupled assay uses HRP to detect the second MAO product, H 2 O 2 , resulting in the conversion of 10-acetyl-3,7-dihydroxyphenoxazine to resorufin. [47] [48] [49] The compounds did not quench the fluorescence of resorufin but most of them inhibited HRP by greater than 30% at 50 µM, the most potent by >80%. The inhibition of HRP by each compound at 5 or 50 µM is given as Supplementary Information (Table S1 ). The most potent HRP inhibitors, all with IC 50 values of around 1 µM, always possessed a phenolic group, either in the 4-position (6, 17, 21 and 23) or 2-position (4) of the phenyl ring.
The phenolic group has previously been associated with HRP inhibition, however on a flavonoid scaffold. 50 In light of these findings, we point out a potential flaw of the coupled Ampliflu™ Red assay, which may produce false positive results. In this study, the HRP inhibition at 1 µM prevented the use of the coupled assay to evaluate MAO inhibition.
Monoamine oxidase activity
To avoid the observed interference issues with the coupled assay, all compounds were evaluated using the kynuramine spectrophotometric assay. 51 All compounds were soluble in assay buffer at 100 μM but absorbed light at the wavelength (314 nm) of the kynuramine assay, limiting the maximum concentration to 30 µM for the initial screen. Compounds selected for further study could be used up to 100 μM. IC 50 values were measured for all compounds using purified MAO-A as shown in Table 2 . Several compounds displayed moderate to low micromolar range of inhibition, allowing selection of compounds for evaluation against membrane-bound MAO-A and MAO-B. IC 50 values for the selected compounds are given in Table 2 .
The selectivity index calculated based on the IC 50 values showed a small selectivity for MAO-B (6, 15, 17, 18 and 19).
ABAD activity
Compounds 3-23 were screened at a fixed 100 µM concentration to evaluate their inhibitory effect on ABAD activity with modified spectrophotometric assay. 26 The majority of the compounds did not significantly inhibit ABAD function. However, compounds 17 and 21 induced a decrease in ABAD activity of 51% or 61%, respectively (Table 2) . Both compounds possess a phenolic group, which appears to be a key feature for displaying inhibition of ABAD. Based on the small effects observed in the 100 µM screen, the determination of IC 50 was not possible since the concentration range needed would exceed the limits of assay. 
Cytotoxicity
To evaluate acute cytotoxicity, all compounds were screened using the standard MTT assay with the CHO-K1 cell line which is commonly used for cytotoxicity screening. 52 The observed toxicity was expressed as LC 50 values ( Table 2 ). The majority of the compounds showed very low levels of toxicity with an LC 50 value over 200 µM compared to parent frentizole, producing valuable results for further investigation. Two compounds (9 and 12) showed elevated toxicity (LC 50 ~2 0-40 µM) but these compounds didn't show any beneficial biological activity.
Blood-brain barrier permeation and physicochemical properties
Penetration across the BBB is an essential property for compounds targeting the CNS. In order to predict passive blood-brain penetration of most promising compounds prepared in the current study (10, 17, 21), a modification of the parallel artificial membrane permeation assay (PAMPA) has been used based on reported protocol. 54 The penetration value (P e ) was derived mathematically from time-dependent changes of the selected compounds' concentrations in two aqueous phases separated by the artificial membrane (see Experimental section). Compounds 10 and 17 showed P e values greater than 4, which indicate sufficient passive transition of the compounds through the BBB (Table 3) . 55, 56 For the physicochemical properties, the number of hydrogen bond donors (HBD), number of hydrogen (Table 4) apparently follow their own trend showing somewhat ambiguous relationship with k and the in silico molecular descriptors. The most striking deviation is exhibited by compound 21 that has a low penetration rate P e despite its sufficient hydrophobicity as implied by relatively high values of ClogP, ClogD and k. This finding may results from overall physicochemical effect of 3,5-dichloro-4-hydroxy aromatic moiety (see Table 1 ) which renders 21 the most ionisable compound at the physiological pH of 7.4 in comparison to 10 and 17. Therefore, it should be noted that the PAMPA (predictive) assay cannot be simplified by high performance liquid chromatography analysis or basic molecular descriptors (HBD/HBA, TPSA, ClogP/D), but it can be replaced in vivo experiments when the predicted values should be verified. a Prediction of blood-brain barrier penetration of drugs expressed as P e ± SEM (*10 -6 cm.s -1 ). High BBB permeation predicted for P e > 4; BBB permeation uncertain for P e between 2.0 and 4.0; low BBB permeation predicted for < 2.0 b Capacity factors k determined by a gradient HPLC method on a reverse C18 stationary phase working in acid polar organic mode (pH ~3.5). The values of k given as mean ± SEM of 24 measurements. c Calculated in ACDLabs PhysChem Suite 12.0
Molecular modelling
A molecular docking study was performed in an attempt to identify the binding modes of compound 19 within the MAO-A and MAO-B active sites. Flexible docking was performed using AutoDock Vina 1.1.2 and the 2Z5X (i.e. MAO-A) and 2V5Z (i.e. MAO-B) protein X-ray structures from the Protein Databank. Figure 2 shows the top-scored docking pose of compound 19 (-10.3 kcal/mol) located within the MAO-A cavity. Compounds can often bind with either end of the molecule close to the flavin in MAO, 57 or in rotated configuration. 58 In the latter article, molecular dynamics were used to understand a change in affinity, but that is beyond the scope of this exploratory study for these relatively weak inhibitors of MAO. 
Structure-activity relationship
Initial evaluation of the compounds on the activity of purified MAO-A identified only compound 10
(para-Br) as giving significant inhibition, with an IC 50 value of 5.9 µM for purified human MAO-A, but several other (mainly para) substitutions were found on µM level (4, 8, 15, 17, 19 ). On the other hand, the introduction of a second phenyl ring connected via an ether (9) or a carbonyl moiety (12) resulted in the loss of activity, indicating the space limitation for the favoured para substituent. In contrast, isoquinolin-5-yl moiety (15) displayed promising inhibition.
For the selected compounds studied on both membrane-bound MAO-A and B, non-selective inhibition was observed only for the parent compound 3 (IC 50 around 60 µM), and with the para-methoxy substituent 8 (IC 50 around 36 µM). All other compounds were more selective for MAO-B. MAO-A inhibition was retained for ortho-hydroxyl-containing compounds (4, 19) particularly with additional chlorine in the para (19) or meta position (17, 19) and also for small lipophilic substitutions such as methoxy moiety (8) For inhibition of ABAD activity, compounds 17 and 21 were the most potent with a 4-hydroxy substitution and additionally chlorine on the distal phenyl ring. The 4-hydroxy moiety alone (6) gave inhibition comparable with other positioned isomers (4 and 5) and not much better than 3 without the hydroxyl group. The introduction of chlorine into the C-3 position (17) increased the inhibitory effect.
Additionally, a second chlorine present in the C-5 position (21) further increased the inhibitory effect, which is in agreement with recently reported findings. 41 Functional groups other than chlorine (20 and 23) were not beneficial. Comparing the discussed compounds with the previously published urea/thiourea/phosphonate series, it shows that the inhibition ability doesn't vary significantly with the linker changes. [38] [39] [40] On the other hand, the bicyclic aromatic scaffold using substituted benzothiazole or other moiety might be a crucial factor. In this case, the introduction of indole moiety seems to be rather unfavourable for ABAD inhibitory ability if compared to previously used benzothiazoles. [38] [39] [40] [41] This fact might be related to either its flipped position and/or missing substitution of the indolyl scaffold, which will be the matter of further investigation.
Taken together, the best MAO and ABAD inhibitors from presented series of compounds do not possess the same structural features required for inhibition of both enzymes, when ABAD inhibition seems to be restricted to the 3-chlorine-4-hydroxy or 3,5-chlorine-4-hydroxy scaffold. The presence of the phenolic moiety particularly influenced the activity on the MAO targets. An improved MAO inhibitory ability (with a degree of MAO-B selectivity) was shown in a decrease of IC 50 with presence of ortho-hydroxy group Importantly, the majority of the tested MAO/ABAD inhibitors shared a low cytotoxic profile (usually one order of magnitude better) compared to parent compound frentizole. Only two compounds (9 and 12)
showed higher cytotoxicity, possibly associated with their increased lipophilicity, since they contain an additional phenyl ring connected via ether or carbonyl linker. However, compounds 9 and 12 did not show biological activity valuable for further investigation.
Conclusion
In summary, a novel class of disubstituted thioureas was synthesized and evaluated for MAO-A, MAO-B
and ABAD inhibitory ability and a cytotoxicity profile. Some compounds showed MAO inhibitory activity in the micromolar range (mostly with modest MAO-B selectivity), expanding the pool of known MAO inhibitors scaffolds. In case of ABAD, the molecular design was only partially successful in retaining ABAD inhibitory ability, with only two compounds showed promising structural features for ABAD inhibition. The majority of the compounds also exhibited HRP inhibitory properties, demonstrating the limitations for the use of the HRP-coupled assay, particularly with compounds possessing phenolic groups. Therefore, we emphasize caution when using coupled enzymatic reactions such as the Amplex™/Ampliflu™ Red assay, and the need to validate positive results with direct or different assays to avoid misconceptions in data interpretation.
Conflict of interest
The authors confirm that this article content has no conflict of interest.
Experimental section
Synthesis
Chemicals and instrumentation
All reagents and solvents were purchased from commercial sources (Sigma Aldrich, Merck) and they were used without any further purification. Obtained mass spectra were processed in Xcalibur 3.0.63 software. Uncalibrated purity > 95% at 254nm
was confirmed for all the studied compounds by HPLC. Elemental analyses were carried out with CE Instruments EA-1110 CHN (CE Instruments, Wigan, UK). Melting points were determined on a Stuart SMP30 melting point apparatus and are uncorrected.
General procedure for the synthesis of isothiocyanates for electron rich aromatic amines (2).
This procedure was employed to generate corresponding isothiocyanates for final thioureas 3-9 and 14-23. The reverse process, where 1H-indole-5-isothiocyanate was firstly generated followed by subsequent coupling with corresponding amine, was used for final thioureas with free phenolic groups (4-7,
17, 19, 21 and 23).
An amine (1; 3 mmol) was dissolved in THF (5 mL). While stirring, CS 2 (30 mmol, 2.28 g, 1.80 mL) and 
General procedure for the synthesis of isothiocyanates electron poor aromatic amines (2).
This procedure was employed to generate corresponding isothiocyanates for final thioureas 10-13.
An amine (1; 3 mmol) was dissolved in THF (10 mL) and cooled on an ice bath. NaH (60% in mineral oil;
1.5 mmol, 0.18 g) was added and mixture was stirred for next 10 min on an ice bath. CS 2 (9 mmol, 0.69 g, 0.54 mL) was added drop-wise and the reaction was allowed to reach room temperature. The mixture was refluxed for 18 h and then cooled on an ice bath. Boc 2 O (2.97 mmol, 0.65 g, 1 mL THF solution) and DMAP (0.03 mmol, 11 mg, 0.5 mL THF solution) were added. The mixture was stirred for next 60 min at room temperature. The solution was acidified with 1 N HCl (15 mL) and extracted with Et 2 O (3×20 mL). The combined organic layers were dried (Na 2 SO 4 ) and the solvent was removed under reduced pressure. The residue was purified by column chromatography (silica gel, heptane-EtOAc, 5:1) to afford isothiocyanate (2), which was directly used in next step.
44,45
General procedure for the synthesis of 1-aryl-3-(1H-indol-5-yl)thiourea (3-23):
The aromatic amine (1 mmol) was dissolved in DCM (5 mL). Solution of isothiocyanate (1 mmol) in DCM (2 mL) was added drop-wise and the mixture was stirred for 20 h at room temperature. 46 Solvent was removed under reduced pressure and the residue was purified by column chromatography (silica gel, 
1-(1H-indol-5-yl)-3-phenylthiourea (3)
Light-yellow solid, yield 0.24 g (90%), mp 159-160 °C. 
N-(4-(3-(1H-indol-5-yl)thioureido)phenyl)acetamide (14)
Beige solid, yield 0.26 g (80%), mp 172-174 °C. 
1-(3-chloro-4-hydroxyphenyl)-3-(1H-indol-5-yl)thiourea (17)
Light-brown solid, yield 0.27 g (85%), mp 152-153 °C. 
In vitro evaluation
Ampliflu™ Red (10-acetyl-3,7-dihydroxyphenoxazine), kynuramine, horseradish peroxidase, human MAO-A and MAO-B (expressed in insect cell membranes) were purchased from Sigma-Aldrich. Human MAO-A from heterologous expression in yeast was purified as previously reported. 51 
Fluorescence quenching and horseradish peroxidase activity assay
No fluorescence quenching of resorufin (1 µM and 10 µM) was observed in the presence of tested compounds (50 µM). Additionally, an inhibitory effect on HRP was evaluated using modified Ampliflu™ Red, where a direct HRP substrate (H 2 O 2 ) was used instead of in-situ MAO-generated H 2 O 2 . 47, 49, 59 The assay mixture with a final volume of 200 µL 50 mM potassium phosphate buffer (pH 7.4) in the well contained; Fluorometric determination of the remaining HRP activity was followed by the fluorescence of the resorufin formed (excitation at 535 nm, emission at 595 nm) at 30°C.
Monoamine oxidase activity assay
The spectrophotometric assays for purified human MAO-A and for membrane-bound human MAO-A/MAO-B are based on the conversion of kynuramine to 4-hydroxyquinoline using reported conditions. 51, 60 The spectrophotometric assay for purified human MAO-A activity in a shown with the standard error of the parameter estimate.
ABAD activity assay
A modified version of ABAD activity assay has been used to determine inhibitory effect of discussed compounds. 26 In-house assay reaction conditions consisted of ABAD enzyme (0.5 μg/mL), NADH (250 μM), acetoacetyl-CoA (120 μM) and a single compound of interest (100 μM, 1% DMSO (v/v)). Solutions were prepared in assay buffer (10 mM HEPES buffer, 0.5% (w/v) gelatin (porcine skin), pH 7.4 at 37°C). Control solutions containing an equivalent concentration of DMSO (1% (v/v)) were also prepared and run concurrently. Reaction progression was measured via a decrease in NADH absorbance at 340 nm using a SpectraMAX M2e spectrophotometer. The reaction period was gated to yield steady state conditions (R 2 > 0.9). Assay validity was demonstrated on compound AG18051 43 and experimental data were included in Supplementary Information (Fig. S1 ).
Cell viability assessment
Standard MTT assay (Sigma Aldrich) was used according to the manufacturer's protocol on the CHO-K1
cell line (Chinese hamster ovary, ECACC, Salisbury, UK) in order to compare the cytotoxic effect of studied compounds. The cells were cultured according to ECACC recommended conditions and seeded in a density of 8000 per well as was described earlier. 52 Briefly, tested compounds were dissolved in DMSO and subsequently in the growth medium (F-12) supplemented with 10% FBS and 1% PEN/STREP so that the final concentration of DMSO did not exceed 0.5% (v/v). Cells were exposed to the tested compounds in the medium (100 µL) for 24 hours. Then this medium was replaced by the medium containing 10 μM of MTT (100 µL) and cells were allowed to produce formazan for another approximately 3 h under surveillance.
Thereafter, medium with MTT was removed and crystals of formazan were dissolved in DMSO (100 µL). Cell viability was assessed spectrophotometrically by the amount of formazan produced. Absorbance was measured at 570 nm, with 650 nm as a reference wavelength on Synergy HT reader (BioTek, USA). LC 50 was then calculated from the control -subtracted triplicates using non-linear regression (four parameters) of GraphPad Prism 5 software. Final LC 50 and SEM value was obtained as a mean of 3 independent measurements. MTT assay was validated with simultaneous tacrine LC 50 determination, which is in agreement with those reported in literature. 49 Triton X (0.1%) has been used as negative control for MTT assay, confirming 100% of cells death.
Prediction of blood-brain barrier permeation
Chemicals and instrumentation
In LC-UV-MS analyses, acetonitrile, formic acid, both of LC-MS grade purity (Sigma Aldrich), and ultrapure water of ASTM I type (resistance 18.2 MΩ.cm at 25°C) prepared by Barnstead Smart2Pure 3 UV/UF (ThermoFisher Scientific, Bremen, Germany) apparatus were used for preparation of mobile phases.
Parallel artificial membrane permeation assay
A modification of the parallel artificial membrane permeation assay (PAMPA) has been used based on reported protocol. 54 The filter membrane of the donor plate was coated with PBL (Polar Brain Lipid, Avanti, USA) in dodecane (4 µL of 20 mg/mL PBL in dodecane) and the acceptor well was filled with 300 µL of PBS 
HPLC analysis
HPLC analysis of the donor and acceptor solutions from the PAMPA assay was carried out using a Dionex UltiMate 3000 analytical system equipped with a Waters Atlantis dC18 (2.1 x 100 mm/3 µm) column as the stationary phase. The elution was performed by a linear gradient method utilizing ultra-pure water Molecular docking runs were performed in AutoDock Vina (v1.1.2) using 24 CPUs in parallel with the exhaustiveness parameter set to 128. 61 Several of the cavity forming residues (MAO-A: Tyr69, Leu97, Gln99, Val101, Phe173, Ile180, Asn181, Ile207, Phe208, Ser209, Val210, Gln215, Lys305, Cys323, Met324, Ile325, Glu327, Ile335, Thr336, Leu337, Met350, Phe352, Tyr407, Tyr444; MAO-B: Ser59, Tyr60, Gln65, His90, Phe99, Phe103, Trp119, Leu164, Leu167, Phe168, Leu171, Cys172, Ile198, Ile199, Ser200, Gln206, Lys296, Ile316, Tyr326, Phe343, Tyr398, Tyr435) were assigned as flexible ones. Flexible docking was repeated 10 times for both enzymes and the top-scored poses were visually inspected with figures generation using PyMOL (v1.7). In each docking run, 9 binding modes with the lowest binding energies were stored to evaluate all significantly contributing ligand-enzyme interactions.
